TY - JOUR T1 - Aberrant levels of cortical myelin distinguish individuals with unipolar depression from healthy controls JF - medRxiv DO - 10.1101/2021.02.25.21252472 SP - 2021.02.25.21252472 AU - David A.A. Baranger AU - Yaroslav O. Halchenko AU - Skye Satz AU - Rachel Ragozzino AU - Satish Iyengar AU - Holly A. Swartz AU - Anna Manelis Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/12/2021.02.25.21252472.abstract N2 - The association of unipolar depression (UD), relative to healthy controls (HC), with cortical myelin is underexplored, despite growing evidence of associations with white matter tract integrity. We characterized cortical myelin in the 360 Glasser atlas regions using the T1w/T2w ratio in 39 UD and 47 HC participants (ages=19-44, 75% female). A logistic elastic net regularized regression with nested cross-validation and a subsequent linear discriminant analysis conducted on held-out samples were used to select brain regions and classify UD vs. HC. True-label model performance was compared against permuted-label model performance. Cortical myelin distinguished UD from HC with 68% accuracy (p<0.001; sensitivity=63.8%, specificity=71.5%). Brain regions contributing to this classification performance were located in the orbitofrontal cortex, anterior cingulate, extended visual, and auditory cortices, and showed statistically significant decreases and increases in myelin levels in UD vs. HC. The patterns of cortical myelin in these regions may be a biomarker of UD.Competing Interest StatementD.A.A.B, Y.O.H., S.S., R.R, S.I., and A.M.: declare no conflict of interest. H.A.S: receives royalties from Wolters Kluwer, royalties and an editorial stipend from APA Press, and honorarium from Novus Medical Education.Funding StatementThis work was supported by a grant from the National Institute of Health R01MH114870 to A.M., and Y.O.H was supported by P41EB019936 to the Center for Reproducible Neuroimaging Computation (PI: Kennedy).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the University of Pittsburgh Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made publicly available upon publication. ER -